| Project/Area Number |
15K10069
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
General surgery
|
|---|
| Research Institution | Juntendo University |
|---|
Principal Investigator |
Shimizu Hideo 順天堂大学, 医学部, 准教授 (50424247)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
堀本 義哉 順天堂大学, 医学部, 准教授 (40424246)
十合 晋作 順天堂大学, 医学部, 准教授 (80365634)
小見山 博光 順天堂大学, 医学部, 非常勤講師 (30348982)
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2016: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2015: ¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
|
|---|
| Keywords | 血中循環癌細胞 / 乳癌 / 上皮間葉移行 |
|---|
| Outline of Final Research Achievements |
The development of CTCs as a predictive marker for treatment effects on breast cancer remains an enormous task. We investigated CTCs, including epithelial mesenchymal transition status, from metastatic breast cancer patients who had received eribulin-based treatment. Twenty-two patients were enrolled and peripheral blood samples were collected before eribulin treatment. CTCs were then examined using a Microfluidic Chip device. CTCs positive for vimentin and pan-cytokeratin were defined as mesenchymal and epithelial CTCs, respectively. Numbers of total CTCs were significantly increased in patients with progressive disease during treatment. Patients with more total and mesenchymal CTCs at baseline had significantly shorter progression-free survival.
|
